Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-213 vs Saccharated Ferric Oxide in Iron-Deficiency Anemia
NCT02731534Phase 3Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- May 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoint: Maximum change in Hemoglobin value at 12 weeks. Started May 2016; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02731534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731534.